leadf
logo-loader
viewFSD Pharma

FSD Pharma taps longtime pharma exec to head its biosciences division

Edward Brennan has served as a medical director at Wyeth-Ayerst Research and GlaxoSmithKline

Boardroom
Brennan also founded IndiPharm, a full-service clinical research organization

FSD Pharma Inc (CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) has named veteran pharmaceutical executive Edward Brennan Jr. as president of its biosciences division.

Brennan has served as a medical director at Wyeth-Ayerst Research and GlaxoSmithKline, where he oversaw ten investigational new drug applications with the US Food and Drug Administration.

He also founded IndiPharm, a full-service clinical research organization that was later acquired by a private equity company.

READ: FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae

“Ed is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development,” CEO Raza Bokhari said. “We aim to capitalize on his expert guidance as FSD builds on our recently announced acquisition of Prismic Pharmaceuticals and continues to execute on our strategy to identify and acquire cannabinoid-based pharmaceutical R&D companies focused on FDA approved clinical trials.”

FSD Pharma is a Toronto-based producer of pharmaceutical-grade cannabis. On April 23, it announced a C$23.4 million acquisition of Prismic, a US pharmaceutical company focused on developing non-addictive drugs to combat the opioid epidemic.

Shares slipped 2.3% to C$0.22 on the CSE and 0.6% to US$0.16 on OTC markets. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: FSD Pharma

Price: 2.1 CAD

CSE:HUGE
Market: CSE
Market Cap: $40.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma fully funded to continue progress on its Phase 2 study on...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive the biopharma group is fully funded to continue progress on its Phase 2 study to treat hospitalized coronavirus patients. Bokhari says its most recent fundraising gives the firm $9.5M to conduct the trial, which will...

3 weeks, 4 days ago

2 min read